Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Heritage Wealth Management Inc.

Heritage Wealth Management Inc. cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,183 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. Heritage Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $463,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Sherman Asset Management Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $162,000. Metis Global Partners LLC boosted its position in shares of Bristol-Myers Squibb by 5.8% during the fourth quarter. Metis Global Partners LLC now owns 106,503 shares of the biopharmaceutical company’s stock worth $6,024,000 after buying an additional 5,859 shares during the period. Xcel Wealth Management LLC lifted its position in Bristol-Myers Squibb by 90.2% in the fourth quarter. Xcel Wealth Management LLC now owns 14,819 shares of the biopharmaceutical company’s stock worth $838,000 after purchasing an additional 7,029 shares during the period. Terril Brothers Inc. lifted its position in Bristol-Myers Squibb by 5.2% in the fourth quarter. Terril Brothers Inc. now owns 158,188 shares of the biopharmaceutical company’s stock worth $8,947,000 after purchasing an additional 7,805 shares during the period. Finally, Maple Capital Management Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $201,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

BMY opened at $59.71 on Friday. The stock has a fifty day moving average of $57.15 and a 200-day moving average of $54.74. The firm has a market capitalization of $121.17 billion, a P/E ratio of -13.51, a PEG ratio of 2.07 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.15%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their target price for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Cantor Fitzgerald upped their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $57.86.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.